1. In Vivo

Bayer Wins Specialty CV Deal

Bayer will pay $50 million up front and up to $335 million in development and commercialization milestones for ex-US rights to Nuvelo's clot-buster alfimeprase, which complements the German group's specialist cardiovascular portfolio.

Nuvelo Inc. wasn't short of suitors for its clot-buster alfimeprase, in Phase III trials for acute peripheral arterial occlusion (PAO) and venous catheter occlusion (CO), when it first starting seeking partners for the drug last year. Phase III assets are rare as it is; even rarer are those with strong data and clear advantages over existing treatments. That mid-sized German group Bayer AG won the booty may seem surprising; less so, however, considering Bayer's cardiology heritage and pipeline--and its willingness to accept ex-US rights only.

Bayer will pay $50 million up front and up to $335 million in development and commercialization milestones for rights to...

More from Business Strategy

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By Jo Shorthouse

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.